期刊文献+

75岁以上老年患者冠脉介入诊疗后造影剂肾病危险因素分析

Analysis of Risk Factors of Radiographic Contrast Nephropathy in Patients over 75 Years Old Undergoing Coronary Artery Intervention
下载PDF
导出
摘要 [目的]分析75岁以上老年人行冠状动脉介入治疗(PCI)后造影剂肾病(CIN)的相关危险因素.[方法]在本院行PCI治疗患者212例,年龄>75岁患者92例(老年组),年龄<75岁者120例(对照组),于PCI治疗前后检测肾功能指标,以肌酐清除率对肾功能损害程度进行分级,并分析危险因素.[结果]212例中有13例(6.13%)患者PCI治疗后发生CIN.老年组CIN发生率为8.69%(8/92),显著高于对照组的4.17%(5/120),老年患者易患CIN的危险因素共在6个方面有统计学意义:212例中:肌酐清除率<60 mL/min、急诊PCI、造影剂用量>150 mL、糖尿病、充血性心力衰竭、高血压,其RR值(95%的可信区间)分别为7.6(6.1~9.8)(P=0.003),5.3(3.7~7.9)(P=0.026),4.8(3.2~6.9)(P=0.028),4.3(3.0~6.6)(P=0.034),3.9(2.9~6.5)(P=0.036) 和2.4(1.4~3.2)(P=0.042).[结论]老年患者行PCI发生CIN风险较高.肾功能不全、急诊PCI、造影剂用量>150 mL、糖尿病、充血性心力衰竭、高血压等6个因素均与老年患者易患CIN有关,其中肾功能不全是最主要的危险因素.
出处 《医学临床研究》 CAS 2012年第6期-,共3页 Journal of Clinical Research
  • 相关文献

参考文献7

  • 1Briguori C,Airoldi F,Morici N. New Pharmacological protocols toprevent or reduce contrast media nephropathy[J].Minerva Cardioangiologica,2005,(01):49-58.
  • 2StevensMA,McCullough PA,Tobin KJ. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy:results of the Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation study[J].Journal of the American College of Cardiology,1999,(02):403-411.
  • 3Mc Cullough PA,Adam A,Becker CR. Epidemiology and prognostic implications of contrast induced nephropathy[J].American Journal of Cardiology,2006,(6A):5K213K.
  • 4邹古明,颜红兵.造影剂肾病的诊断与治疗现状[J].中国介入心脏病学杂志,2005,13(3):194-196. 被引量:78
  • 5Bartholomew BA. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification[J].American Journal of Cardiology,2004,(12):1515-1519.
  • 6WalkerPD,BrikeringKL,Theobald JC. Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy:a review[J].Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy,2003,(02):1617-1626.
  • 7郑华,屠燕,马立勤.冠心病患者经皮冠状动脉介入术后并发造影剂肾病的危险因素分析及防治策略探讨[J].南方医科大学学报,2011,31(7):1273-1276. 被引量:32

二级参考文献47

  • 1Soma VR, Cavusoglu E, Vidhun R, et al. Contrast-associated nephropathy[J]. Heart Dis, 2002, 4(6): 372-9.
  • 2Senoo T, Motohiro M, Kamihata H, et al. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome [J]. Am J Cardiol, 2010, 105(5): 624-8.
  • 3Barrett B J, Parfrey PS. Preventing nephropathy induced by contrast medium[J]. N E1agl J Med, 2006, 354(4): 379-86.
  • 4Toprak O, Cirit M. Risk Factors for contrast-induced nephropathy [J]. Kindney Blood Press Res, 2006, 29(2): 84-93.
  • 5Solomon R. Contrast-induced nephropathy: update with special emphasis on patients with diabetes[J]. Curt Diab Pep, 2007, 7(6): 454-8.
  • 6Tumlin J, Stacul F, Adam A, et al. Pathophysiology of contrast-induced nephropathy[J]. Am J Cardio, 2006, 98(6): 14-20.
  • 7Heyman SN, BrezisM, Ep stein FH, et al. Early renal medullary hypoxic injury from radio-contrast and indomethacin [J]. KidneyInt, 1991, 40: 632-42.
  • 8Fiaccadori E, Maggiore U, Rotelli C, et al. Plasma and urinary free 3-nitrotyrosine following cardiac angiography procedures with nonionic radio-contrast media[J]. Nephrol Dial Transplant, 2004, 19: 865-9.
  • 9Lepor NE. A review of pharmacologic interventions to prevent contrast-induced nephropathy [J]. Rev Cardiovasc Med, 2003, 4( Suppl 5): S34-S42.
  • 10Lameier NH. Contrast-induced nephropathy-prevention and risk reduction[J]. Nephrol Dial Transplant, 2006, 21(6): 11-23.

共引文献106

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部